All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The combination of elotuzumab, pomalidomide, and dexamethasone (EloPd) was investigated as part of the ELOQUENT-3 (NCT02654132) trial leading to its approval in patients with relapsed/refractory multiple myeloma (RRMM) who have received ≥2 prior therapies, including lenalidomide and a proteasome inhibitor.1
Here, we summarize a publication by Gentile et al.1 in Haematologica on real-world experiences and outcomes in patients with RRMM treated with EloPd compared with the clinical trial data from ELOQUENT-3.
Figure 1. Overall response rate*
CR, complete response; ORR, overall response rate; PR, partial response; VGPR, very good PR.
*Data from Gentile, et al.1
Figure 2. 12-month PFS and OS rates by characteristic*
ASCT, autologous stem cell transplant; CrCL, creatinine clearance; ISS, International Staging System; LOT, line of therapy; mo, month; OS, overall survival; PFS, progression-free survival.
*Data from Gentile, et al.1
Key learnings |
---|
|
Subscribe to get the best content related to multiple myeloma delivered to your inbox